Karen Reckamp, MD
Medical Oncology · Duarte, CANPI 1649290248
Payments from drug & device makers
Across 274 payments — averaging $11,274 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1.3M
- Blueprint Medicines Corporation$605K
- Clovis Oncology, Inc.$298K
- Daiichi Sankyo Inc.$245K
- Genentech, Inc.$106K
- Boehringer Ingelheim$81K
- plus $478K from 23 others
Across 30 payments — averaging $1206.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$26K
- F. Hoffmann-la Roche AG$3K
- GSK$3K
- Tesaro, Inc.$2K
- Novartis Pharma AG$2K
- Novartis$353
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 95 | $1,276,526 |
| Blueprint Medicines Corporation | 26 | $605,176 |
| Clovis Oncology, Inc. | 3 | $298,388 |
| Daiichi Sankyo Inc. | 20 | $245,120 |
| Genentech, Inc. | 11 | $105,624 |
| Boehringer Ingelheim | 2 | $80,563 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $73,654 |
| Eli Lilly | 16 | $70,241 |
| Spectrum Pharmaceuticals Inc. | 3 | $56,909 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $53,489 |
| AbbVie | 3 | $42,029 |
| GSK | 13 | $40,188 |
| AstraZeneca | 20 | $35,880 |
| E.r. Squibb & Sons, L.L.C. | 3 | $30,805 |
| Seagen Inc. | 3 | $26,306 |
| EMD Serono, Inc. | 4 | $13,330 |
| Amgen | 8 | $8,525 |
| Acerta Pharma LLC | 1 | $6,518 |
| Pfizer | 7 | $4,193 |
| Astrazeneca UK Limited | 1 | $4,163 |
| Partner Therapeutics, Inc. | 6 | $3,211 |
| Immunitybio, Inc. | 1 | $2,500 |
| F. Hoffmann-la Roche AG | 3 | $1,998 |
| Johnson & Johnson | 3 | $1,529 |
| Novocure Inc. | 1 | $1,380 |
| Ipsen Biopharmaceuticals, Inc | 1 | $610 |
| Genentech USA, Inc. | 1 | $116 |
| Galvanize Therapeutics, Inc | 1 | $104 |
| Novartis | 1 | $46 |
How this compares
$3,089,118 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Duarte
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Daneng LiDuarte$12.4M
- Tanya DorffDuarte$8.7M
- Erminia MassarelliDuarte$7.2M
- Joseph ChaoDuarte$4M
- Yan XingDuarte$2.8M
- Adam RockDuarte$2.7M
- Marianna KoczywasDuarte$2.3M
- Dani CastilloDuarte$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.